57 DOCUMENTO SIPREC 2022 endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J Am Coll Cardiol. 2009;53:1309-17. 28. Khan A, Patel NK, O’Heam DJ, et al. Resistant hypertension and obstructive sleep apnea. Int J Hypertens. 2013:193010 29. Gami AS, Olson EJ, Shen WK, et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10701 adults. J Am Coll Cardiol. 2013;62:610-6. 30. Kotsis V, Nilsson P, Grassi G, et al. New developments in the pathogenesis of obesity-induced hypertension. J Hypertens. 2015;33:1499-1508. 31. Para I, Albu A, Porojan MD. Adipokines and arterial stiffness in obesity. Medicina. 2021;57:653 32. Hall JE, do Carmo JM, da Silva AA, et al. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol. 2019;15:367-85. 33. Aroor R, Jia G, Sowers JR. Cellular mechanisms underlying obesity-induced arterial stiffness. Am J Physiol Integr Comp Physiol. 2018;314:R387-R398. 34. Kotsis V, Stabouli S, Papakatsika S, et al. Mechanisms of obesity-induced hypertension. Hypertens Res. 2010;33:386-93. 35. Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017;122:1-7 36. Messerli FH, Christie B, DeCarvalho JG, et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med. 1981;141:81-5. 37. Frolich ED. Obesity and hypertension. Hemodynamic aspects. Ann Epidemiol. 1991;1:287-93. 38. Levy Y, Elias N, Cogan U, et al. Abnormal erythrocyte rheology in patients with morbid obesity. Angiology. 1993;44:713-7. 39. Alpert MA, Karthikeyan K, Abdullah O, et al. Obesity and cardiac remodeling in adults: mechanisms and clinical implications. Prog Cardiovasc Dis. 2018;61:114-23. 40. Cuspidi C, Rescaldani M, Sala C, et al. Left-ventricular hypertrophy and obesity: a systematic review and meta-analysis of echocardiographic studies. J Hypertens. 2014;32:16-25. 41. Grassi G, Seravalle G, Dell’Oro R, et al. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000;36:538-42. 42. Hall JE, Crook ED, Jones DW, et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci. 2002;324:127-137. 43. Carlstrom M, Wilcox CS, Arendshorst WJ. Renal autoregulation in health and disease. Physiol Rev. 2015;95:405-511. 44. Fu Y, et al. Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralcorticoid receptors. Hypertension. 2012;6:1183-92. 45. Granger JP, et al. Role of nitric oxide in modulating renal function and arterial pressure during chronic aldosterone excess. Am J Physiol. 1999;276:R197-R202. 46. Sugerman H, Windsor A, Bessos M, et al. Intra-abdominal pressure. Sagittal abdominal diameter and obesity comorbidity. J Intern Med. 1997;241:71-79. 47. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med. 2001;79:21-29. 48. Virdis A, Masi S, Colucci R et al. Microvascular endothelial dysfunction in patients with obesity. Curr Hypertens Rep. 2019;21:32 49. Grassi G, Seravalle G, Scopelliti F, et al. Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity. Obesity. 2010;18:92-98. 50. Aroor AR, Demarco VG, Jia G, et al. The role of tissue renin-angiotensin-aldosterone system in
RkJQdWJsaXNoZXIy NDUyNTU=